natgillin/translations-raw huggingface dataset:
What do you need to know before you take Suboxone
Što morate znati prije nego počnete uzimati Suboxone
• Breathing problems
• Problemi s disanjem
A carcinogenicity study with buprenorphine/naloxone was conducted in rats at doses of 7, 30 and 120 mg/kg/day, with estimated exposure multiples of 3 to 75 times, based on a human daily sublingual dose of 16 mg calculated on a mg/m² basis.
Ispitivanje kancerogenosti buprenorfina/naloksona provedeno je na štakorima s dozama od 7, 30 i 120 mg/kg/dan, čime su štakori bili izloženi 3 do 75 puta višoj dozi, s obzirom na dnevnu sublingvalnu dozu za ljude od 16 mg izračunatu na temelju mg/m2.
General warnings relevant to the administration of opioids Opioids may produce orthostatic hypotension in ambulatory patients.
Opća upozorenja vezana uz primjenu opioida Opioidi mogu izazvati ortostatsku hipotenziju u vanbolničkih bolesnika.
Therefore the potential to overdose with a full agonist exists, especially when attempting to overcome buprenorphine partial agonist effects, or when buprenorphine plasma levels are declining.
Stoga postoji mogućnost predoziranja punim agonistom, naročito kad se pokušavaju poništiti učinci parcijalnog agonista buprenorfina ili kad su razine buprenorfina u plazmi u opadanju.
Detailed information on this medicine is available on the website of the European Medicines Agency http://www.ema.europa.eu/
Detaljne informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove: http://www.ema.europa.eu/
Symptoms of overdose may include feeling sleepy and uncoordinated with slowed reflexes, blurred vision, and/or slurred speech.
Simptomi predoziranja mogu obuhvaćati osjećaj pospanosti, slabu koordinaciju s usporenim refleksima, zamagljeni vid i/ili nerazgovjetan govor.
In this trial, 326 heroin-addicted subjects were randomly assigned to either buprenorphine/naloxone 16 mg per day, 16 mg buprenorphine per day or placebo.
U ovom ispitivanju, 326 ispitanika ovisnih o heroinu randomizirano je na 16 mg/dan buprenorfina/naloksona, 16 mg/dan buprenorfina, ili placebo.
Slow or difficult breathing, liver injury with or without jaundice, hallucinations, swelling of face and throat or life threatening allergic reactions, drop in blood pressure on changing position from sitting or lying down to standing.
Usporeno ili otežano disanje, oštećenje jetre s ili bez žutice, halucinacije, natečenost lica i ždrijela ili po život opasne alergijske reakcije, pad krvnog tlaka pri promjeni položaja iz sjedećeg ili ležećeg u uspravni.
Do not use this medicine after the expiry date which is stated on the carton.
Ne upotrebljavajte ovaj lijek nakon isteka roka trajanja koji je naveden na pakiranju.
Naloxone is an antagonist at -opioid receptors.
Nalokson je antagonist µ-opioidnih receptora.
If you or someone else takes too much of this medicine, you must go or be taken immediately to an emergency centre or hospital for treatment as overdose with Suboxone may cause serious and lifethreatening breathing problems.
Ako uzmete više lijeka Suboxonea nego što ste trebali Ako se Vi ili netko drugi predozira ovim lijekom, odmah treba otići ili biti odvezen u ambulantu hitne pomoći ili bolnicu zbog liječenja jer predoziranje lijekom Suboxone može uzrokovati ozbiljne i životno ugrožavajuće poteškoće s disanjem.
This product may cause drowsiness, dizziness, or impaired thinking, especially during treatment induction and dose adjustment.
Ovaj lijek može izazvati pospanost, omaglicu ili umanjiti sposobnost razmišljanja, osobito tijekom početka liječenja i prilagodbe doze.
Co-administration during buprenorphine/naloxone treatment is contraindicated due to the potentially dangerous interaction that may precipitate a sudden onset of prolonged and intense opioid withdrawal symptoms (see section 4.3).
Njihova istodobna primjena za vrijeme liječenja buprenorfinom/naloksonom je kontraindicirana zbog potencijalno opasnih interakcija koje bi mogle naglo uzrokovati duge i intenzivne simptome ustezanja od opioida (vidjeti dio 4.3).
Dansom Lane
Dansom Lane, Hull,
• if you have serious liver problems
• ako imate ozbiljne probleme s jetrom
Name and address of the manufacturer responsible for batch release Reckitt Benckiser Healthcare (UK) Ltd
Naziv(i) i adresa(e) proizvođača odgovornog(ih) za puštanje serije lijeka u promet Reckitt Benckiser Healthcare
Alcohol may increase drowsiness and may increase the risk of respiratory failure if taken with Suboxone.
Alkohol može pojačati omamljenost i rizik od zatajenja disanja ako se uzima s lijekom Suboxone.
Also tell your doctor immediately if you experience side effects such as:
Također se odmah obratite svojem liječniku ako primijetite nuspojave poput:
N-dealkylbuprenorphine is a -opioid agonist with weak intrinsicactivity.
N-dealkilbuprenorfin je µ-opioidni agonist sa slabom intrinzičkom aktivnošću.
Do not take Suboxone
Nemojte uzimati Suboxone
No dose modification based on renal function is required but caution is recommended when dosing subjects with severe renal impairment (see Section 4.3).
Nije potrebna prilagodba doze vezano uz funkciju bubrega, ali se preporučuje oprez kad se doza primjenjuje u osoba s teškim oštećenjem funkcije bubrega (vidjeti dio 4.3).
To minimize the risk of misuse, abuse and diversion, physicians should take appropriate precautions when prescribing and dispensing buprenorphine, such as to avoid prescribing multiple refills early in treatment, and to conduct patient follow-up visits with clinical monitoring that is appropriate to the patient's needs.
Da bi se smanjio rizik pogrešne uporabe, zlouporabe lijeka i uporabe lijeka u svrhe za koje nije namijenjen, liječnici moraju poduzeti odgovarajuće mjere opreza pri propisivanju i davanju buprenorfina, poput izbjegavanja propisivanja višestrukih količina lijeka na početku liječenja te provođenja praćenja stanja bolesnika kliničkim praćenjem sukladno potrebama bolesnika.
The medicinal product is metabolized in the liver, primarily by glucuronide conjugation, and excreted in the urine.
Ovaj se lijek metabolizira u jetri, primarno konjugacijom s glukuronskom kiselinom, a izlučuje se urinom.
Effect of hepatic impairment on pharmacokinetic parameters of buprenorphine and naloxone following SUBOXONE administration (change relative to healthy subjects)
Tablica 2. Utjecaj oštećenja jetre na farmakokinetičke parametre buprenorfina i naloksona nakon primjene lijeka SUBOXONE (relativna promjena u odnosu na zdrave ispitanike)
Plasma levels of buprenorphine increased with the sublingual dose of buprenorphine/naloxone.
Razine buprenorfina u plazmi povećale su se sublingvalnom primjenom buprenorfina/naloksona.
The long half life of methadone should be considered when starting buprenorphine/naloxone.
Dug poluvijek metadona treba uzeti u obzir kad se započinje s liječenjem buprenorfinom/naloksonom.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Neiskorišteni lijek ili otpadni materijal treba biti zbrinuti sukladno lokalnim propisima.
The combination (4:1) of buprenorphine hydrochloride and naloxone hydrochloride was not mutagenic in a bacterial mutation assay (Ames test), and was not clastogenic in an in vitro cytogenetic assay in human lymphocytes or in an intravenous micronucleus test in the rat.
Kombinacija (4:1) buprenorfin klorida i nalokson hidroklorida nije imala mutagene učinke u ispitivanju mutagenosti na bakterijama (Amesov test) i nije bila klastogenična u citogenetičkom ispitivanju in vitro na ljudskim limfocitima ili u intravenskom mikronukleusnom testu u štakora.
14.0-fold increase
Povećanje od 14,0 puta
• if you have serious breathing problems
• ako imate ozbiljne poteškoće s disanjem
Oedema peripheral
Bol Periferni edem
After a satisfactory stabilisation has been achieved the frequency of dosing may be decreased to dosing every other day at twice the individually titrated daily dose.
Nakon što se postigla zadovoljavajuća stabilizacija, učestalost primjene može se smanjiti na svaki drugi dan, s time da se daje dvostruka dnevna doza koju pojedini bolesnik inače prima.
o For patients receiving methadone, the dose of methadone should be reduced to a maximum of 30 mg/day before beginning buprenorphine/naloxone therapy.
o Za bolesnike koji dobivaju metadon, doza metadona mora se sniziti na najviše 30 mg dnevno prije početka terapije buprenorfinom/naloksonom.
On Day 3, those randomized to receive buprenorphine/naloxone were switched to the combination tablet.
3. dana, ispitanici randomizirani u skupinu koja će primati buprenorfin/nalokson prebačeni su na kombiniranu tabletu.
o CYP3A4 inhibitors: an interaction study of buprenorphine with ketoconazole (a potent inhibitor of CYP3A4) resulted in increased Cmax and AUC (area under the curve) of buprenorphine (approximately 50 % and 70 % respectively) and, to a lesser extent, of norbuprenorphine.
o inhibitorima CYP3A4: ispitivanje interakcija buprenorfina s ketokonazolom (jaki inhibitor CYP3A4) rezultiralo je povećanjem Cmax (za 50 %) i AUC (područje ispod krivulje) (za 70 %) buprenorfina, i u manjoj mjeri, norbuprenorfina.
Patients should be clearly monitored during the switching period from buprenorphine or methadone to buprenorphine/naloxone since withdrawal symptoms have been reported.
Bolesnike treba strogo pratiti tijekom razdoblja prelaska s buprenorfina ili metadona na buprenorfin/nalokson s obzirom na prijavljene simptome ustezanja.
Long-term administration of buprenorphine during the last three months of pregnancy may cause a withdrawal syndrome in the neonate (e.g. hypertonia, neonatal tremor, neonatal agitation, myoclonus or convulsions).
Dugoročna primjena buprenorfina u zadnjem tromjesečju trudnoće može izazvati sindrom ustezanja u novorođenčeta (npr. hipertoniju, neonatalni tremor, neonatalnu agitaciju, mioklonus ili konvulzije).
• Keep the tablets in place under the tongue until they have completely dissolved.
• Držite tablete na mjestu pod jezikom sve dok se potpuno ne otope.
Concomitant administration of opioid antagonists (naltrexone, nalmefene) for the treatment of alcohol or opioid dependence.
Istodobna primjena antagonista opioida (naltrekson, nalmefen) za liječenje ovisnosti o alkoholu ili opioidima.
Combining buprenorphine with naloxone in Suboxone is intended to deter misuse and abuse of the buprenorphine.
Kombiniranje buprenorfina s naloksonom u lijeku Suboxone namijenjeno je odvraćanju od pogrešne uporabe i zlouporabe buprenorfina.
- The other ingredients are lactose monohydrate, mannitol, maize starch, povidone K30, citric acid anhydrous, sodium citrate, magnesium stearate, acesulfame potassium and natural lemon and lime flavour.
- Drugi sastojci su laktoza hidrat, manitol, kukuruzni škrob, povidon K30, bezvodna citratna kiselina, natrijev citrat, magnezijev stearat, acesulfamkalij i prirodna aroma limuna i limete.
Buprenorphine is an opioid partial agonist/antagonist which binds to the  and  (kappa) opioid receptors of the brain.
Buprenorfin je parcijalni agonist/antagonist opioida koji se veže za µ i κ (kappa) opioidne receptore u mozgu.
Renal elimination may be prolonged since 30 % of the administered dose is eliminated by the renal route.
Oštećenje bubrega Eliminacija bubrezima može biti produljena, jer se 30% primijenjene doze eliminira putem bubrega.
Not Known
Manje često Nepoznato
Prior to treatment initiation, consideration should be given to the type of opioid dependence (i.e. longor short-acting opioid), the time since last opioid use and the degree of opioid dependence.
Prije početka liječenja, mora se utvrditi o kojoj se vrsti ovisnosti o opioidima radi (tj. kratkodjelujućim ili dugodjelujućim opioidima), vremenu od zadnje uporabe opioida te stupnju ovisnosti o opioidima.
Depending upon the findings, the medicinal product may be discontinued cautiously so as to prevent withdrawal symptoms and to prevent a return to illicit drug use.
Ovisno o nalazima, može se prekinuti davanje lijeka, ali uz oprez, tako da se spriječi nastanak simptoma ustezanja od lijeka i povrat na zlouporabu lijeka.
This product should be used with care in patients with asthma or respiratory insufficiency (e.g. chronic obstructive pulmonary disease, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, pre-existing respiratory depression or kyphoscoliosis (curvature of spine leading to potential shortness of breath)).
Ovaj lijek treba primjenjivati uz oprez u bolesnika s astmom ili respiratornom insuficijencijom ( npr. kronična opstruktivna bolest pluća, plućno srce, smanjeni kapacitet pluća, hipoksija, hiperkapnija, prethodno postojeća depresija disanja ili kifoskolioza (iskrivljenje kralježnice koje vodi do potencijalno kratkog daha)).
To avoid precipitating withdrawal, induction with buprenorphine/naloxone or buprenorphine only should be undertaken when objective and clear signs of withdrawal are evident (demonstrated e.g. by a score indicating mild to moderate withdrawal on the validated Clinical Opioid Withdrawal Scale, COWS).
Da bi se izbjeglo naglo ustezanje, buprenorfin/nalokson ili sam buprenorfin trebaju se uvesti samo kad objektivni i jasni znakovi ustezanja postanu očiti (pokazuju se, primjerice, rezultatom koji upućuje na blago do umjereno ustezanje na validiranoj Kliničkoj skali ustezanja od opioida (COWS)).
How to take Suboxone
Kako uzimati Suboxone
The spectrum of abnormalities ranges from transient asymptomatic elevations in hepatic transaminases to case reports of hepatic failure, hepatic necrosis, hepatorenal syndrome, hepatic encephalopathy and death.
Poremećaji su se kretali u rasponu od prolaznih asimptomatskih povišenja jetrenih transaminaza do pojedinačnih prikaza slučajeva zatajenja jetre, nekroze jetre, hepatorenalnog sindroma, hepatalne encefalopatije i smrti.
The lowest dose studied represented exposure multiples of 1x for buprenorphine and 5x for naloxone at the maximum human therapeutic dose calculated on a mg/m² basis.
Najniža ispitivana doza kojoj su štakori bili izloženi odgovarala je umnošcima od 1x izloženosti za buprenorfin i 5x za nalokson pri maksimalnoj terapijskoj dozi za ljude izračunate na temelju mg/m2.
Some people have died from respiratory failure (inability to breathe) because they misused this medicine or took it in combination with other central nervous system depressants, such as alcohol, benzodiazepines (tranquilisers), or other opioids.
Neke su osobe umrle zbog zatajenja disanja (nisu mogle disati), jer su uzele ovaj lijek na pogrešan način ili su ga uzele u kombinaciji s drugim depresorima središnjeg živčanog sustava,
Sudden withdrawal syndrome caused by taking Suboxone too soon after use of illicit opioids, drug withdrawal syndrome in newborn.
Iznenadni sindrom ustezanja uzrokovan preranim uzimanjem lijeka Suboxone nakon primjene zabranjenih opioida, sindrom ustezanja lijeka u novorođenčadi.
However, when administered intravenously to opioid-dependent persons, the presence of naloxone in Suboxone produces marked opioid antagonist effects and opioid withdrawal, thereby deterring intravenous abuse.
Međutim, kad ga intravenski primjenjuju osobe ovisne o opioidima, prisutnost naloksona u lijeku Suboxone izaziva izrazite učinke opioidnog antagonista i ustezanja opioida, što odvraća osobe od intravenske zlouporabe.
Baseline liver function tests and documentation of viral hepatitis status is recommended prior to commencing therapy.
Prije početka terapije preporučuje se napraviti i dokumentirati osnovne pretrage funkcije jetre i status virusnog hepatitisa.
Abrupt discontinuation of treatment is not recommended as it may result in a withdrawal syndrome that may be delayed in onset.
Ne preporučuje se nagli prekid terapije, jer on može uzrokovati sindrom ustezanja lijeka koji može imati odgođeni nastup.
The dose can be made up from multiple Suboxone tablets of different strengths, which may be taken all at the same time or in two divided portions; the second portion to be taken directly after the first portion has dissolved.
Doza koja može biti sačinjena od više Suboxone tableta različitih jačina, može se uzeti istovremeno ili u dva podijeljena dijela; drugi dio treba uzeti odmah nakon što se prvi dio otopi.
Drug withdrawal syndrome neonatal (see section 4.6)
Neonatalni sindrom ustezanja (vdjeti dio 4.6)
As buprenorphine/naloxone pharmacokinetics may be altered in patients with hepatic impairment, lower initial doses and careful dose titration in patients with mild to moderate hepatic impairment are recommended.
S obzirom na to da farmakokinetika buprenorfina/naloksona može biti izmijenjena u bolesnika s oštećenjem jetre, preporučuju se niže početne doze i pažljivo titriranje doze u bolesnika s blagim do umjerenim oštećenjem jetre.
Insomnia (inability to sleep), constipation, nausea, excessive sweating, headache, drug withdrawal syndrome
Nesanica (nemogućnost spavanja), zatvor stolice, mučnina, znojenje, glavobolja, sindrom ustezanja lijeka
It is unknown whether naloxone is excreted in human breast milk.
Nije poznato izlučuje li se nalokson u majčino mlijeko.
Suboxone should be used cautiously when co-administered with:
Suboxone treba primjenjivati uz oprez kod istovremene primjene s:
The dose of buprenorphine or the CYP3A4 inducer may need to be adjusted accordingly.
U skladu s tim potrebno je prilagoditi dozu buprenorfina ili induktora CYP3A4.
Table 3 summarizes the results from a clinical trial in which the exposure after single-dose administration of Suboxone 2.0/0.5mg (buprenorphine/naloxone) sublingual tablet was determined in healthy subjects, and in subjects with hepatic impairment.
Tablica 2. objedinjuje rezultate kliničkog ispitivanja u kojem je izloženost nakon primjene jednokratne doze lijeka Suboxone 2,0/0,5 mg (buprenorfin/nalokson) sublingvalne tablete određena u zdravih osoba i u osoba s oštećenjem jetre.
Each sublingual tablet contains 156.64 mg lactose (as monohydrate) For the full list of excipients, see section 6.1.
Svaka sublingvalna tableta sadrži 156,64 mg laktoze (kao monohidrat) Za cjeloviti popis pomoćnih tvari, vidjeti dio 6.1.
If you are dependent upon heroin or a short acting opioid, your first dose of Suboxone should be taken when signs of withdrawal appear, but not less than 6 hours after you last used opioids.
Ako ste ovisni o heroinu ili kratkodjelujućim opioidima, prvu dozu lijeka Suboxone trebate uzeti kad se pojave znakovi ustezanja, no ne ranije od 6 sati od zadnjeg uzimanja opioida.
Suboxone sublingual tablets should be used with caution in patients with moderate hepatic impairment (See section 4.3 and 5.2).
Suboxone sublingvalne tablete moraju se primjenjivati s oprezom u bolesnika s umjerenim oštećenjem jetre (vidjeti dijelove 4.3 i 5.2).
o CYP3A4 inducers: Concomitant use of CYP3A4 inducers with buprenorphine may decrease buprenorphine plasma concentrations, potentially resulting in sub-optimal treatment of opioid dependence with buprenorphine.
induktorima CYP3A4: Istodobna primjena induktora CYP3A4 s buprenorfinom može sniziti koncentraciju buprenorfina u plazmi te potencijalno rezultirati suboptimalnim liječenjem ovisnosti o opioidima buprenorfinom.
Patients should be monitored for signs and symptoms of precipitated opioid withdrawal, toxicity or overdose caused by increased levels of naloxone and/or buprenorphine.
Bolesnici moraju biti pod nadzorom zbog znakova i simptoma ustezanja opioida, toksičnosti ili predoziranja uzrokovanih povišenom razinom naloksona i/ili buprenorfina.
Severe Hepatic Impairment (Child-Pugh Class C) (n=8)
Teško oštećenje jetre (Child-Pughov stupanj C) (n=8)
In many cases the presence of pre-existing mitochondrial impairment (genetic disease, liver enzyme abnormalities, infection with hepatitis B or hepatitis C virus, alcohol abuse, anorexia, concomitant use of other potentially hepatotoxic medicines) and ongoing injecting drug use may have a causative or contributory role.
U mnogim slučajevima, prisutnost postojećih mitohondrijskih oštećenja (genetskih bolesti, abnormalnosti jetrenih enzima, infekcije virusom hepatitisa B ili C, alkoholizma, anoreksije, uz istovremenu primjenu drugih potencijalno hepatotoksičnih lijekova) i aktualna intravenska uporaba sredstava ovisnosti mogli su prouzročiti ove promjene ili im doprinijeti.
Buprenorphine is a partial agonist at the µ (mu)-opiate receptor and chronic administration produces dependence of the opioid type.
Buprenorfin je parcijalni agonist µ (mi)-opioidnih receptora i kronična primjena dovodi do ovisnosti opioidnog tipa.
Overall, buprenorphine plasma exposure increased approximately 3-fold in patients with severely impaired hepatic function, while naloxone plasma exposure increased 14-fold with severely impaired hepatic function.
Sveukupno, izloženost buprenorfinu u plazmi povećana je približno 3 puta, a izloženost naloksona u plazmi povećana je 14 puta u bolesnika s teškim oštećenjem funkcije jetre.
The first dose of Suboxone should be taken when signs of withdrawal appear, but not less than 24 hours after you last used methadone.
Prvu dozu lijeka Suboxone trebate uzeti kad se pojave znakovi ustezanja, no ne ranije od 24 sata od zadnjeg uzimanja metadona.
In cases of intravenous drug misuse, some adverse experiences are attributed to the act of misuse rather than the medicinal product and include local reactions, sometimes septic (abscess, cellulitis), and potentially serious acute hepatitis, and other acute infections such as pneumonia, endocarditis have been reported (see section 4.4).
U slučajevima intravenske zlouporabe lijeka, neke nuspojave su prije povezane s činom zloupotrebe, nego s lijekom i zabilježene su lokalne reakcije, ponekad septičke (apsces, celulitis), i potencijalno ozbiljan akutni hepatitis te druge akutne infekcije kao što su pneumonija, endokarditis (vidjeti dio 4.4).
If you have any further questions on the use of this product, ask your doctor or pharmacist.
U slučaju bilo pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku ili ljekarniku.
For subjects randomized to either active treatment, dosing began with 8 mg of buprenorphine on Day 1, followed by 16 mg (two 8 mg) of buprenorphine on Day 2.
Za ispitanike randomizirane u jednu od dvije skupine koje su primale djelatnu tvar, doziranje je započelo s 8 mg buprenorfina 1. dana, a 2. dana ispitanici su dobili 16 mg (dvaput po 8 mg) buprenorfina.
For example, a patient stabilised to receive a daily dose of 8 mg buprenorphine may be given 16 mg buprenorphine on alternate days, with no dose on the intervening days.
Na primjer, bolesniku čije je stanje stabilno uz dnevnu dozu od 8 mg buprenorfina može se dati 16 mg buprenorfina svaki drugi dan, bez primjene lijeka u međuvremenu.
Opioid agonist ceiling effects were observed during clinical pharmacology studies in opioid-dependent persons.
U ispitivanjima kliničke farmakologije primjećeni su “učinci plafona” uz opioidne agoniste u osoba ovisnih o opioidima.
Mild Hepatic Impairment (Child-Pugh Class A) (n=9)
Blago oštećenje jetre (Child-Pughov stupanj A) (n=9)
Keep out of the sight and reach of children and other household members.
Kako čuvati Suboxone Držite izvan pogleda i dosega djece ili drugih članova kućanstva.
Each sublingual tablet contains 168 mg lactose (as monohydrate) For the full list of excipients, see section 6.1.
Svaka sublingvalna tableta sadrži 168 mg laktoze (kao monohidrat) Za cjeloviti popis pomoćnih tvari, vidjeti dio 6.1.
28 tablets in blister packs Paper/Aluminium/Nylon/Aluminium/PVC.
7 tableta u papir/aluminij/najlon/aluminij/PVC blister pakiranju . 28 tableta u papir/aluminij/najlon/aluminij/PVC blister pakiranju.
Caution is recommended when dosing patients with severe renal impairment (creatinine clearance <30 ml/min) (see sections 4.2 and 5.2).
Preporučuje se oprez prilikom doziranja bolesnika s teškim oštećenjima bubrega (klirens kreatinina <30 ml/min) (vidjeti dijelove 4.2 i 5.2).
A patent airway and assisted or controlled ventilation must be assured.
Potrebno je osigurati prohodnost dišnih puteva te asistirano ili kontrolirano disanje.
• anti-retrovirals (used to treat HIV) such as ritonavir, nelfinavir, indinavir may increase the effects of this medicine.
• antiretrovirotici (koriste se za liječenje HIV-a) poput ritonavira, nelfinavira i indinavira mogu povećati učinke ovog lijeka.
Uncommon side effects (may effect up to 1 in 100 people):
Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba):